Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-04-23 Audit Report / Informat…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
240418 Board Report Statutory Accounts FY2023 -NL-vF.pdf
Audit Report / Information Classification · 98% confidence The document is explicitly titled "JAARVERSLAG VAN DE RAAD VAN BESTUUR BETREFFENDE DE ENKELVOUDIGE JAARREKENING PER 31 DECEMBER 2023" (Annual Report of the Board of Directors concerning the Individual Annual Accounts as of December 31, 2023). It contains detailed financial statements (Balance Sheet, Income Statement analysis), management discussion, and going concern assessment for a full fiscal year (ending December 31, 2023). Although the text is in Dutch, the content structure and purpose align perfectly with a comprehensive annual financial report. While the US equivalent is 10-K, for non-US entities, the comprehensive annual report is often classified as 'AR' (Audit Report/Information) or sometimes '10-K' if it serves the primary annual reporting function. Given the detailed nature covering the entire year and including the Board's report, it is the primary annual filing. Since '10-K' is defined as the 'Official yearly report covering company activity and full financial performance,' and this document serves that exact function for this Belgian company, '10-K' is the most appropriate classification among the provided options for a full annual report, even if it's not technically a US SEC Form 10-K. FY 2023
2024-04-23 Dutch
Auditor report- Consolidated Accounts 31 12 23 NL.pdf
Audit Report / Information Classification · 98% confidence The document is titled "VERSLAG VAN DE COMMISSARIS AAN DE ALGEMENE VERGADERING VAN AANDEELHOUDERS VAN SEQUANA MEDICAL NV OVER DE GECONSOLIDEERDE JAARREKENING VOOR HET BOEKJAAR AFGESLOTEN OP 31 DECEMBER 2023" (Report of the Commissioner to the General Meeting of Shareholders of Sequana Medical NV on the Consolidated Annual Accounts for the Financial Year Ended December 31, 2023). It contains a formal 'Verslag over de geconsolideerde jaarrekening' (Report on the consolidated annual accounts) issued by an external auditor (PwC) providing an unqualified opinion ('Oordeel zonder voorbehoud') on the consolidated financial statements for the year ended December 31, 2023. This structure—a formal auditor's report accompanying the full annual financial statements for the fiscal year—is characteristic of a comprehensive Annual Report filing, which corresponds to the 10-K definition, even though the text is in Dutch and references local Belgian law, the substance aligns with the annual reporting requirement. It is not an Earnings Release (ER) because it is the full audited report, not just highlights. It is not an Audit Report (AR) because it is explicitly tied to the full annual accounts for the fiscal year, making it part of the 10-K package. It is not an AGM-R or DEF 14A as it is the financial report itself, not the meeting materials or remuneration report, although it is addressed to the AGM. FY 2023
2024-04-23 Dutch
AGM EGM 2024 - Overview of Voting Rights (ENG_NL).pdf
AGM Information Classification · 98% confidence The document is titled 'AANTAL AANDELEN EN STEMRECHTEN GEWONE EN BUITENGEWONE ALGEMENE VERGADERINGEN' (Outstanding Shares and Voting Rights Ordinary and Extraordinary General Meetings) and specifies a date for the meeting (May 23, 2024). It details the current number of outstanding shares and potential shares issuable upon exercise of options and warrants, which is information directly related to shareholder voting rights and the structure of the upcoming General Meeting. This content strongly aligns with the purpose of providing information necessary for a shareholder vote or related to the meeting itself. Since it details the voting rights and share structure relevant to the AGM, it is best classified as AGM Information (AGM-R), as it is preparatory material for the meeting, rather than the formal voting results (DVA) or a general proxy statement (PSI).
2024-04-23 Dutch
AGM EGM 2024 - Special Board Report Authorized Capital (ENG) (executed).pdf
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "SPECIAL REPORT OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ARTICLE 7:199 OF THE BELGIAN COMPANIES AND ASSOCIATIONS CODE". This report relates to a proposal to renew the board of directors' power to increase the company's share capital under the authorised capital, which is a matter concerning capital structure and shareholder authorization. This directly aligns with the definition of a document detailing capital/financing activities or proposals submitted to shareholders for approval, which falls under the 'Capital/Financing Update' category (CAP). Although it is a report submitted to a general shareholders' meeting (which might suggest AGM-R or PSI), the core subject is the authorization mechanism for capital changes, making CAP the most precise fit among the provided options. It is a formal report, not just a brief announcement of a report (RPA/RNS).
2024-04-23 English
AGM EGM 2024 - Proxy form (NL_ENG).pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is explicitly titled "VOLMACHT" (PROXY) and details the process for a shareholder to appoint a representative (proxy holder) to attend and vote at the "GEWONE EN BUITENGEWONE ALGEMENE VERGADERINGEN" (Ordinary and Extraordinary General Meetings) scheduled for May 23, 2024. This document is a form used to grant voting authority for a shareholder meeting, which falls under the category of materials related to shareholder meetings and voting procedures. The definition for AGM Information (AGM-R) covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. While this is a proxy form rather than a presentation, it is intrinsically linked to the AGM process. However, the document explicitly states: "Deze volmacht is geen verzoek tot verlening van volmacht overeenkomstig de bepalingen van artikelen 7:144 of 7:145 van het Wetboek van vennootschappen en verenigingen." This exclusion suggests it is not a standard Proxy Solicitation Statement (PSI). Given the context of granting authority for the AGM, AGM-R is the most appropriate fit among the provided options, as it relates directly to the mechanics of the Annual General Meeting.
2024-04-23 Dutch
AGM EGM 2024 - Convertible Loan Contributions - Board Report (ENG) (executed).pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled "REPORT OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ARTICLES 7:179 AND 7:197 OF THE BELGIAN COMPANIES AND ASSOCIATIONS CODE". It details a proposal by the board of directors to the extraordinary general shareholders' meeting (EGM) to increase share capital via a contribution in kind of outstanding receivables (debt conversion). This document provides the justification, valuation, and consequences of a proposed corporate action requiring shareholder approval, which is characteristic of materials presented to shareholders for a vote at a general meeting. Since it is a report justifying a proposal to be voted on at an EGM, it strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. While it is a report, it is specifically tied to the voting process for a major corporate action, making PSI a better fit than a general report code like AR or IR.
2024-04-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.